{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:50:57Z","timestamp":1775872257693,"version":"3.50.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nanoparticle albumin-bound paclitaxel (nab-PTX) is a novel formulation that combines paclitaxel with human serum albumin via nanotechnology. Without the need for solubilizers, it allows for higher safe doses, shorter infusion time, and no premedication for hypersensitivity prevention. nab-PTX has been widely used in the treatment of various solid tumors. Its common adverse reactions include fatigue, alopecia, myelosuppression, etc., while pulmonary toxicity is extremely rare. To date, there are no reports of severe drug-induced interstitial lung disease (DILD) caused by nab-PTX in gastric cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a case of a 77-year-old male patient with gastric adenocarcinoma. On the 15th day after receiving second-line nab-PTX monotherapy, the patient developed chest tightness, dyspnea, high fever, and severe respiratory distress. High-resolution computed tomography (HRCT) of the chest showed diffuse exudative changes in both lungs, involving more than 90% of the lung fields. After excluding other causes such as pulmonary infection and tumor progression, the patient was diagnosed with severe nab-PTX-related DILD. nab-PTX was discontinued immediately, and the patient was treated with intravenous methylprednisolone sodium succinate. Subsequently, the pulmonary inflammation was gradually absorbed, and the clinical symptoms were significantly improved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>nab-PTX-induced severe interstitial pneumonia in gastric cancer patients is a rare and life-threatening adverse event. Clinicians should closely monitor respiratory symptoms and signs of patients receiving nab-PTX, achieve early identification and timely intervention, so as to reduce the risk of adverse outcomes and improve patient prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1792694","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:28:35Z","timestamp":1772083715000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Nanoparticle albumin-bound paclitaxel -induced severe interstitial lung disease in a gastric cancer patient: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Baosheng","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Weifang Hospital of Traditional Chinese Medicine","place":["Weifang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaihui","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Weifang Hospital of Traditional Chinese Medicine","place":["Weifang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianru","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Weifang Hospital of Traditional Chinese Medicine","place":["Weifang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuli","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Weifang People\u2019s Hospital","place":["Weifang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric cancer, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Ajani","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7150\/jca.12986","article-title":"Evolving evidence of the efficacy and safety of nab-paclitaxel in the treatment of cancers with squamous histologies","volume":"7","author":"Loong","year":"2016","journal-title":"J Cancer."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-019-01516-9","article-title":"Treatment rationale and design for J-SONIC: A randomized study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis","volume":"19","author":"Otsubo","year":"2018","journal-title":"Clin Lung Cancer."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-019-01516-9","article-title":"Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study","volume":"24","author":"Fukuizumi","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S88023","article-title":"Albumin-bound paclitaxel in solid tumors: Clinical development and future directions","volume":"24","author":"Kundranda","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-006-0388-1","article-title":"Suspected paclitaxel-induced pneumonitis","volume":"9","author":"Shitara","year":"2006","journal-title":"Gastric Cancer."},{"key":"B8","article-title":"Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer","volume":"32","author":"Tamiya","year":"2012","journal-title":"Anticancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy180","article-title":"Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer","volume":"49","author":"Kashiwada","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1586\/14737140.2013.817684","article-title":"Antineoplastic therapy-induced pulmonary toxicity","volume":"13","author":"Sadowska","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2019190036","article-title":"Immune checkpoint inhibitor therapy-related pneumonitis: patterns and management","volume":"39","author":"Kalisz","year":"2019","journal-title":"Radiographics."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1159\/000504968","article-title":"Enhance the importance and knowledge of drug-induced lung injury","volume":"40","author":"Xu","year":"2017","journal-title":"Chin J Tuberc Respir Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1159\/000504968","article-title":"Immunotherapy-Induced Airway Disease: A New Pattern of Lung Toxicity of Immune Checkpoint Inhibitors","volume":"99","author":"Mitropoulou","year":"2020","journal-title":"Respiration"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.11.027","article-title":"Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: A position paper from the fleischner society","volume":"159","author":"Johkoh","year":"2021","journal-title":"Chest."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.05.02","article-title":"Tyrosine kinase inhibitors interstitial pneumonitis: diagnosis and management","volume":"8","author":"He","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-13-39","article-title":"Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches","volume":"13","author":"Matsuno","year":"2012","journal-title":"Respir Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00349.2010","article-title":"Altered expression of tight junction molecules in alveolar septa in lung injury and fibrosis","volume":"302","author":"Ohta","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3760\/cma.j.cn112152-20220412-00244","article-title":"Expert consensus on the diagnosis and treatment of anticancer drug-induced interstitial lung disease","volume":"44","year":"2022","journal-title":"Chin J Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000479148","article-title":"Interstitial lung disease following single-agent nanoparticle albumin-bound paclitaxel treatment in patients with advanced non-Small cell lung cancer","volume":"10","author":"Nakatani","year":"2017","journal-title":"Case Rep Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1792694\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:28:37Z","timestamp":1772083717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1792694\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":20,"alternative-id":["10.3389\/fonc.2026.1792694"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1792694","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"article-number":"1792694"}}